GE Healthcare tops its C-Pro cell processing system with SpinOculation, an automation software that enables closed T cells transduction at the preferred volume and concentration.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
GE Healthcare’s Edison platform collaborates with ACR AI-Lab to extend its AI capabilities and allows ACR members access to algorithm creation in an aim to turn research into product development.
The dozens of ‘devastating, unprecedented and dangerous’ forest fires raging across Sweden are far from manufacturing and industrial centres, says Swedish Association of the Pharmaceutical Industry.
Cell therapy firms will be able to authenticate the foetal bovie serum (FBS) they use through a testing programme launched by GE Healthcare and Oritain.
Stem Cell Theranostics has secured rights to the technology it uses to make cellular heart disease models for drug development through a deal with GE Healthcare.
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
GE Healthcare has started designing a vaccine manufacturing facility for an unnamed drug company, just days after expanding its collaboration with plant-cell production technology firm iBio.
Sartorius Stedium Biotech (SSB) and GE Healthcare Life Sciences say new cross licensing deal will aid development of their respective biomanufacturing tech offerings.
GE Healthcare says its new range of sample collection cards reduce sample volumes needed for drug metabolism across pharmacokinetics (DMPK) in all stages of drug development process.
GE Healthcare has bought label-free molecular interaction analysis expert MicroCal to bolster its label-free analysis offering to life science and pharmaceutical customers.
GE Healthcare has announced its intention to invest $20m in radical
new technology, which will allow laboratory research results to be
transmitted and shared amongst doctors worldwide setting to define
a new age in patient care.
Two products aimed at enhancing the efficiency of process
development in biopharmaceutical manufacturing are the latest
offerings from GE Healthcare, the UK-based medical technology and
services company.
Invitrogen has immersed itself in yet more legal wrangling after
the life sciences firm filed a patent lawsuit against GE Healthcare
alleging 'wilful' infringement of its intellectual property.
GE Healthcare has reported its fourth quarter and full year
financial results in a tough 12 months that have seen the
laboratory imaging and diagnostics company feel the full force of
US Government regulatory pressure.
GE Healthcare and Novavax have a vision - a state-of-the-art
pandemic influenza vaccine manufacturing facility solution with the
ability to produce vaccines quickly, which can be marketed as a
product to international countries.
Tecan and GE Healthcare Life Sciences division are collaborating to
simplify high throughput (HT) protein purification by increasing
the speed and reliability of expression screening programmes.
LabTechnologist.com brings you an exclusive interview with Ger
Brophy - general manager of Advanced Systems within GE Healthcare's
Life Science Division.
GE Healthcare and the Bio Affinity Company (BAC) have extended
their biopharmaceutical partnership to develop purification media
for Factor VIII (FVIII) for the treatment of haemophilia A.
GE Healthcare has recently launched a number of diverse and
transformational medical technologies aimed at improving
productivity across the pharmaceutical manufacturing sector.
GE Healthcare has launched two new products designed to meet
growing industry needs for the purification of monoclonal
antibodies, one of the fastest growing drug classes in the drug
industry.
General Electric has completed its €8.1 billion acquisition of UK
healthcare company Amersham, promising to create a new company that
will 'change the face of healthcare,' according to GE chief
executive Jeffrey Immelt.
General Electric's €8.1 billion acquisition of the UK's Amersham
was approved by the European Union yesterday, after it concluded
that the deal would not create a monopoly in Europe's medical
imaging market.
General Electric is the company offering to buy Amersham of the UK,
it was confirmed today. The US group is offering £5.7 billion for
the life sciences group, and said it has no plans to hive off
Biosciences.
